About this episode

This episode discusses the management of follicular lymphoma with expert Dr. Gilles Salles.

In this episode, we discuss the management of follicular lymphoma with Dr. Gilles Salles from Memorial Sloan Kettering Cancer Center. Here are the articles we discussed: 1. Relevance of Bone Marrow Biopsy in Follicular Lymphoma: https://pubmed.ncbi.nlm.nih.gov/35787017/ 2. TROG 99.03 (RCT of Systemic Therapy after Involved-Field Radiotherapy in Patients with Early-Stage Follicular Lymphoma): https://pubmed.ncbi.nlm.nih.gov/29975623/ 3. Long-term follow-up results of RCT comparing early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumor burden follicular lymphoma: https://pubmed.ncbi.nlm.nih.gov/40306831/ 4. RELEVANCE RCT: Lenalidomide plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma: https://ascopubs.org/doi/10.1200/JCO.22.00843 5. GALLIUM RCT: Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL. https://pubmed.ncbi.nlm.nih.gov/37404773/ https://pubmed.ncbi.nlm.nih.gov/28976863/ 6. Long-term follow-up of mosunetuzumab in relapsed/refractory FL: https://pubmed.ncbi.nlm.nih.gov/39447094/ 7. Epcoritamab in relapsed/refractory FL…

People in this episode

Hosts: Rajshekhar Chakraborty, Ashwin Kishtagari, Edward Cliff

Guest: Dr. Gilles Salles

Topics covered

• follicular lymphoma
• cancer management
• oncology research
• clinical trials
• treatment options

Keywords

• follicular lymphoma
• Dr. Gilles Salles
• cancer treatment
• clinical trials
• rituximab

Mentioned in this episode

Organizations: Memorial Sloan Kettering Cancer Center

Books & works: Relevance of Bone Marrow Biopsy in Follicular Lymphoma, TROG 99.03 (RCT of Systemic Therapy after Involved-Field Radiotherapy in Patients with Early-Stage Follicular Lymphoma), Long-term follow-up results of RCT comparing early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumor burden follicular lymphoma, RELEVANCE RCT: Lenalidomide plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma, GALLIUM RCT: Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL, Long-term follow-up of mosunetuzumab in relapsed/refractory FL, Epcoritamab in relapsed/refractory FL, Phase 3 inMIND RCT: Tafasitamab plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma, Long term follow-up results from the Phase 3 PRIMA trial of rituximab maintenance

More episodes of Blood Cancer Talks

• Episode 70. ASH 2025 Myeloid Neoplasm Roundup with Dr. Curtis Lachowiez · February 27, 2026 · 57 min
• Episode 69. ASH 2025 Lymphoma Roundup with Dr. Carla Casulo · January 22, 2026 · 44 min
• Episode 68. ASH 2025 Myeloma Special: MajesTEC-3 and the Bispecific Revolution with Dr. Luciano Costa · January 2, 2026 · 46 min
• Episode 67. Management of CMV in Hematologic Malignancies · November 23, 2025 · 40 min
• Episode 66. International Myeloma Society 2025 Annual Meeting Updates with Dr. Alfred Garfall: The Bispecific Bonanza · October 15, 2025 · 52 min
• Episode 65. Circulating Tumor DNA in DLBCL with Dr. Ash Alizadeh and Dr. David Russler-Germain · September 24, 2025 · 53 min

Explore listener stats, chart rankings, contacts and more on the Blood Cancer Talks podcast page.